{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:19:50Z","timestamp":1790731190349,"version":"4.1.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jbspin.2018.10.004","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T17:57:13Z","timestamp":1539280633000},"page":"437-443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["How should we manage asymptomatic hyperuricemia?"],"prefix":"10.1016","volume":"86","author":[{"given":"G\u00e9rard","family":"Chal\u00e8s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2018.10.004_bib0005","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3899\/jrheum.170806","article-title":"The rising incidence of gout and the increasing burden of comorbidities: A population-based study over 20 years","volume":"45","author":"Elfishawi","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0010","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National health and nutrition examination survey 2007\u20132008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0015","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key002","article-title":"Gout: state of the art after a decade of developments","author":"Pascart","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0020","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41584-018-0040-6","article-title":"From hyperuricaemia to gout: what are the missing links?","volume":"14","author":"Liot\u00e9","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","article-title":"Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options","volume":"15","author":"Bardin","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0030","doi-asserted-by":"crossref","first-page":"e13048","DOI":"10.1111\/ijcp.13048","article-title":"Uric acid and cardiovascular risk: What genes can say","volume":"72","author":"Kei","year":"2018","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0035","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jacc.2015.10.086","article-title":"Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study","volume":"67","author":"Keenan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0040","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/j.ajkd.2017.12.009","article-title":"Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National kidney foundation","volume":"71","author":"Johnson","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0045","doi-asserted-by":"crossref","first-page":"j2376","DOI":"10.1136\/bmj.j2376","article-title":"Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies","volume":"357","author":"Li","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7326\/0003-4819-131-1-199907060-00003","article-title":"Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study","volume":"131","author":"Culleton","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0055","doi-asserted-by":"crossref","first-page":"80688","DOI":"10.18632\/oncotarget.21079","article-title":"Asymptomatic hyperuricemia and coronary artery disease in elderly patients without comorbidities","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0060","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.40472","article-title":"U-Shaped association between serum uric acid level and risk of mortality: a cohort study","volume":"70","author":"Cho","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0065","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jbspin.2015.01.002","article-title":"Hyperuricemia starts at 360 micromoles (6\u2009mg\/dL)","volume":"82","author":"Bardin","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0075","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","article-title":"Asymptomatic hyperuricemia. Risks and consequences in the normative aging study","volume":"82","author":"Campion","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0080","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/annrheumdis-2017-212288","article-title":"Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis","volume":"77","author":"Dalbeth","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0085","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3899\/jrheum.160452","article-title":"Serum uric acid and the risk of incident and recurrent gout: A systematic review","volume":"44","author":"Shiozawa","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0090","series-title":"Crystal-induced arthropathies","first-page":"7","article-title":"The epidemiology of gout and calcium pyrophosphate dehydrate deposition disease","author":"Saag","year":"2006"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0095","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1136\/annrheumdis-2012-201916","article-title":"Serum urate association with hypertension in young adults: analysis from the coronary artery risk development in young adults cohort","volume":"72","author":"Gaffo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1759720X15599734","article-title":"Hyperuricaemia with deposition: latest evidence and therapeutic approach","volume":"7","author":"Perez-Ruiz","year":"2015","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0105","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/nrrheum.2014.139","article-title":"Screening for hyperuricaemia and gout: a perspective and research agenda","volume":"10","author":"Stamp","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0110","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/15257770802136040","article-title":"Asymptomatic hyperuricemia: impact of ultrasonography","volume":"27","author":"Puig","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0115","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/acr.20527","article-title":"Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: concordance between readers","volume":"63","author":"Howard","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0120","doi-asserted-by":"crossref","first-page":"R4","DOI":"10.1186\/ar3223","article-title":"Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: an ultrasound controlled study","volume":"13","author":"Pineda","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0125","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/ard.2011.154997","article-title":"Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study","volume":"71","author":"De Miguel","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0130","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1186\/2193-1801-3-592","article-title":"Hidden gout \u2013 ultrasound findings in patients with musculo-skeletal problems and hyperuricemia","volume":"3","author":"Reuss-Borst","year":"2014","journal-title":"Springerplus"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0135","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/acr.23082","article-title":"Ultrasound features of the first metatarsophalangeal joint in gout and asymptomatic hyperuricemia: comparison with normouricemic individuals","volume":"69","author":"Stewart","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0140","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jdiacomp.2017.12.015","article-title":"Ultrasonographic assessment of joint pathology in type 2 diabetes and hyperuricemia: the Fremantle diabetes study phase II","volume":"32","author":"Keen","year":"2018","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0145","doi-asserted-by":"crossref","DOI":"10.1002\/acr.23549","article-title":"Levels of cytokines and microRNAs in individuals with asymptomatic hyperuricemia and ultrasonographic findings of gout: a bench-to-bedside approach","author":"Estevez-Garcia","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0150","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/1756-185X.12194","article-title":"Features of urate deposition in patients with gouty arthritis of the foot using dual-energy computed tomography","volume":"18","author":"Sun","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0155","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1136\/annrheumdis-2014-206397","article-title":"Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study","volume":"74","author":"Dalbeth","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0160","doi-asserted-by":"crossref","first-page":"e000593","DOI":"10.1136\/rmdopen-2017-000593","article-title":"Identification of monosodium urate crystal deposits in patients with asymptomatic hyperuricemia using dual-energy CT","volume":"4","author":"Wang","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0165","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/BOR.0000000000000028","article-title":"Definition of hyperuricemia and gouty conditions","volume":"26","author":"Bardin","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0170","first-page":"816","article-title":"An exploratory ultrasound study of early gout","volume":"29","author":"Ottaviani","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0175","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.semarthrit.2015.11.014","article-title":"Prevalence of monosodium urate deposits in a population of rheumatoid arthritis patients with hyperuricemia","volume":"45","author":"Petsch","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0180","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1002\/art.40572","article-title":"Monosodium urate crystal deposits are common in asymptomatic sons of people with gout \u2013 the sons of gout study","volume":"70","author":"Abhishek","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0185","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/annrheumdis-2012-202301","article-title":"A systematic review of ultrasonography in gout and asymptomatic hyperuricaemia","volume":"72","author":"Chowalloor","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0190","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1136\/annrheumdis-2014-205304","article-title":"Hyperuricaemia and gout: time for a new staging system?","volume":"73","author":"Dalbeth","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0195","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0200","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1097\/HJH.0000000000000701","article-title":"Serum uric acid and the risk of cardiovascular and renal disease","volume":"33","author":"Borghi","year":"2015","journal-title":"J Hypertens"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0205","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jare.2016.11.004","article-title":"Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review","volume":"8","author":"Sharaf El Din","year":"2017","journal-title":"J Adv Res"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0210","first-page":"860","article-title":"An update on the animal models in hyperuricaemia research","volume":"35","author":"Zhu","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2008.05.022","article-title":"Uric acid: a marker of increased cardiovascular risk","volume":"202","author":"Gagliardi","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0220","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1161\/HYPERTENSIONAHA.117.10370","article-title":"Uric acid is a strong risk marker for developing hypertension from prehypertension: a 5-year Japanese cohort study","volume":"71","author":"Kuwabara","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0225","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/MNH.0b013e328330d9d0","article-title":"Uric acid: a novel mediator and marker of risk in chronic kidney disease?","volume":"18","author":"Feig","year":"2009","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0230","doi-asserted-by":"crossref","first-page":"e0193622","DOI":"10.1371\/journal.pone.0193622","article-title":"An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout","volume":"13","author":"Desai","year":"2018","journal-title":"PLOS One"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0235","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000464260","article-title":"Elevated serum uric acid level predicts rapid decline in kidney function","volume":"45","author":"Kuwabara","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0240","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.atherosclerosis.2013.08.023","article-title":"Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies","volume":"231","author":"Zhao","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0245","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/acr.20065","article-title":"Hyperuricemia and coronary heart disease: a systematic review and meta-analysis","volume":"62","author":"Kim","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0250","series-title":"Gout & other crystal arthropathies","first-page":"226","article-title":"Asymptomatic hyperuricemia: cardiovascular and renal implications","author":"Neogi","year":"2012"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0255","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000484274","article-title":"The pathophysiology of uric acid on renal diseases","volume":"192","author":"S\u00e1nchez-Lozada","year":"2018","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0260","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1093\/ndt\/gft029","article-title":"Uric acid and chronic kidney disease: which is chasing which?","volume":"28","author":"Johnson","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0265","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/ndt\/gfx341","article-title":"Uric acid in chronic kidney disease: the quest for causality continues","volume":"33","author":"Zoccali","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0270","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s10157-016-1288-2","article-title":"Time to target uric acid to retard CKD progression","volume":"21","author":"Kumagai","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0275","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1471-2369-15-122","article-title":"Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies","volume":"15","author":"Li","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0280","doi-asserted-by":"crossref","first-page":"e100801","DOI":"10.1371\/journal.pone.0100801","article-title":"Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies","volume":"9","author":"Zhu","year":"2014","journal-title":"PLOS One"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0285","doi-asserted-by":"crossref","first-page":"e76827","DOI":"10.1371\/journal.pone.0076827","article-title":"Serum uric acid and chronic kidney disease: the role of hypertension","volume":"8","author":"Sedaghat","year":"2013","journal-title":"PLOS One"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0290","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13075-018-1558-3","article-title":"Untangling the complex relationships between incident gout risk, serum urate, and its comorbidities","volume":"20","author":"Sun","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0295","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12882-016-0433-1","article-title":"Hyperuricemia increases the risk of acute kidney injury: a systematic review and meta-analysis","volume":"18","author":"Xu","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0300","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.metabol.2016.05.009","article-title":"Serum uric acid and mortality in chronic kidney disease: A systematic review and meta-analysis","volume":"65","author":"Xia","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0305","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000484280","article-title":"Uric acid: the lower the better?","volume":"192","author":"Bellomo","year":"2018","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0310","doi-asserted-by":"crossref","first-page":"e0187550","DOI":"10.1371\/journal.pone.0187550","article-title":"Effects of uric acid-lowering therapy in patients with chronic kidney disease: a meta-analysis","volume":"12","author":"Su","year":"2017","journal-title":"PLOS One"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0315","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/0886022X.2018.1456463","article-title":"Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"40","author":"Liu","year":"2018","journal-title":"Ren Fail"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0320","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jare.2017.05.001","article-title":"Asymptomatic hyperuricemia and chronic kidney disease: narrative review of a treatment controversial","volume":"8","author":"Eleftheriadis","year":"2017","journal-title":"J Adv Res"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0325","doi-asserted-by":"crossref","first-page":"e0161","DOI":"10.1097\/MD.0000000000010161","article-title":"Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: a PRISMA-compliant article","volume":"97","author":"Zeng","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0330","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1440-1797.2011.01446.x","article-title":"Management of asymptomatic hyperuricaemia in patients with chronic kidney disease by Japanese nephrologists: a questionnaire survey","volume":"16","author":"Nakaya","year":"2011","journal-title":"Nephrology"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0335","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.atherosclerosis.2018.01.017","article-title":"Hyperuricemia as a prognostic factor after acute coronary syndrome","volume":"269","author":"Lopez-Pineda","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0340","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/art.39581","article-title":"Silent monosodium urate crystal deposits are associated with severe coronary calcification in asymptomatic hyperuricemia: an exploratory study","volume":"68","author":"Andr\u00e9s","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0345","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1007\/s10067-017-3851-y","article-title":"Asymptomatic hyperuricemia: is it time to intervene?","volume":"36","author":"Paul","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0350","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1161\/HYPERTENSIONAHA.112.196980","article-title":"Uric acid reduction rectifies prehypertension in obese adolescents","volume":"60","author":"Soletsky","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0355","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pharmthera.2016.12.004","article-title":"Allopurinol as a therapeutic option in cardiovascular disease","volume":"172","author":"Okafor","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0360","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12872-018-0757-9","article-title":"Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Bredemeier","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0365","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","article-title":"Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) sTUDY","volume":"131","author":"Givertz","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0370","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3899\/jrheum.121231","article-title":"Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach","volume":"41","author":"Akkineni","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0375","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.semarthrit.2016.07.015","article-title":"Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution","volume":"46","author":"Stamp","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0380","doi-asserted-by":"crossref","first-page":"i47","DOI":"10.1093\/rheumatology\/kex432","article-title":"Cardiac and renal protective effects of urate-lowering therapy","volume":"57","author":"Richette","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0385","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1210\/jc.2015-2527","article-title":"Serum uric acid levels and risk of metabolic syndrome: A dose-response meta-analysis of prospective studies","volume":"100","author":"Yuan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0390","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1097\/HJH.0000000000001721","article-title":"Uric acid and risk of new-onset metabolic syndrome, impaired fasting glucose and diabetes mellitus in a general Italian population: data from the pressioni arteriose monitorate e loro associazioni study","volume":"36","author":"Bombelli","year":"2018","journal-title":"J Hypertens"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0395","doi-asserted-by":"crossref","first-page":"e56864","DOI":"10.1371\/journal.pone.0056864","article-title":"High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies","volume":"8","author":"Lv","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0400","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11892-018-0985-5","article-title":"Does altered uric acid metabolism contribute to diabetic kidney disease pathophysiology?","volume":"18","author":"Gul","year":"2018","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0405","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","article-title":"Japanese society of gout and nucleic acid metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition","volume":"30","author":"Yamanaka","year":"2011","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0410","first-page":"329","article-title":"Severe cutaneous adverse reactions due to inappropriate medication use","volume":"179","author":"Chaby","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0415","doi-asserted-by":"crossref","first-page":"i35","DOI":"10.1093\/rheumatology\/kex422","article-title":"How to prevent allopurinol hypersensitivity reactions?","volume":"57","author":"Stamp","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0420","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/bjd.14649","article-title":"Risk assessment of drug-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a disproportionality analysis using the French pharmacovigilance database","volume":"175","author":"Agier","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0425","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jbspin.2015.07.011","article-title":"Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment","volume":"83","author":"Bardin","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0430","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11926-017-0626-z","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome and the rheumatologist","volume":"19","author":"Adwan","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0435","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0440","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S2213-8587(18)30029-9","article-title":"FIELD investigators. Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study","volume":"6","author":"Waldman","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0445","doi-asserted-by":"crossref","first-page":"d8190","DOI":"10.1136\/bmj.d8190","article-title":"Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study","volume":"344","author":"Choi","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0450","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/BOR.0b013e328335ef38","article-title":"A prescription for lifestyle change in patients with hyperuricemia and gout","volume":"22","author":"Choi","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0455","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s13075-014-0495-z","article-title":"The relationship of apolipoprotein B and very low density lipoprotein triglyceride with hyperuricemia and gout","volume":"16","author":"Rasheed","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0460","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1002\/art.39813","article-title":"Effects of the Dietary Approaches to Stop Hypertension (DASH) diet and sodium intake on serum uric acid","volume":"68","author":"Juraschek","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0465","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s10067-017-3613-x","article-title":"DASH diet and change in serum uric acid over time","volume":"36","author":"Tang","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0470","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.amjmed.2016.06.040","article-title":"Update on importance of diet in gout","volume":"129","author":"Beyl","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0475","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00296-013-2690-7","article-title":"Mediterranean diet intervention for patients with hyperuricemia: a pilot study","volume":"34","author":"Chatzipavlou","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0480","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/gerona\/glt028","article-title":"Mediterranean diet and risk of hyperuricemia in elderly participants at high cardiovascular risk","volume":"68","author":"Guasch-Ferr\u00e9","year":"2013","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0485","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/imj.12661","article-title":"Comprehensive dietary education in treated gout patients does not further improve serum urate","volume":"45","author":"Holland","year":"2015","journal-title":"Intern Med J"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0490","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3899\/jrheum.140459","article-title":"Lifestyle interventions for the treatment of gout: a summary of 2 Cochrane systematic reviews","volume":"92","author":"Moi","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0495","doi-asserted-by":"crossref","first-page":"i51","DOI":"10.1093\/rheumatology\/kex421","article-title":"Education and non-pharmacological approaches for gout","volume":"57","author":"Abhishek","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0500","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1136\/annrheumdis-2017-211472","article-title":"Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies","volume":"76","author":"Nielsen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0505","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3109\/07435800.2015.1094085","article-title":"Synergistic association of changes in serum uric acid and triglycerides with changes in insulin resistance after walking exercise in community-dwelling older women","volume":"41","author":"Kawamoto","year":"2016","journal-title":"Endocr Res"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0510","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1136\/annrheumdis-2014-205312","article-title":"Attenuating the mortality risk of high serum uric acid: the role of physical activity underused","volume":"74","author":"Chen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.10.004_bib0515","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrneph.2010.186","article-title":"Challenges of conducting a trial of uric-acid-lowering therapy in CKD","volume":"7","author":"Badve","year":"2011","journal-title":"Nat Rev Nephrol"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X18304020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X18304020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T07:51:12Z","timestamp":1720684272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X18304020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":103,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1297319X18304020"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2018.10.004","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How should we manage asymptomatic hyperuricemia?","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2018.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}